摘要
This study was performed in order to evaluate the toxicities, progression-free and overall survival of patients with responsive residual or recurrent ovarian cancer treated with high-dose chemotherapy. Twenty-seven patients were treated. Doxorubicin, 165 mg/m2 over 96 h (days -12 to -8), etoposide 700 mg/m2 every day ×3 (days -6 to -4), and cyclophosphamide 4.2 g/m2 on d -3 was followed by stem cells and granulocyte colony-stimulating factor. The median days of granulocyte count <500/μl was 14 (range 10-42) and platelets <20 000/μl was 13 (range 2-80). Median numbers of red cell and platelet transfusions were 15 (5-16) and 14 (4-103). Toxicity included mucositis requiring narcotic analgesia in all patients. Asymptomatic decreases in ejection fraction to values <50% were observed in four patients. No clinical congestive heart failure was observed. One death due to sepsis was observed. Median progression-free survival is 7.5 months (1.0-56 months); five patients remain alive, two of whom remain progression-free at 19.5 and 24.5 months post transplant. Median overall survival is 14.0 months (1-68 months). We conclude that high-dose anthracyclines may be safely administered to ovarian cancer patients. The short overall and progression-free survivals observed in our population suggest that this combination is not optimal.
原文 | 英語 |
---|---|
頁(從 - 到) | 859-863 |
頁數 | 5 |
期刊 | Bone Marrow Transplantation |
卷 | 28 |
發行號 | 9 |
DOIs | |
出版狀態 | 已發佈 - 2001 |
對外發佈 | 是 |
ASJC Scopus subject areas
- 血液學
- 移植